CVM - CEL-SCI Corporation Forward Price-to-Revenue Multiple
The expected P/S valuation demonstrates market expectations for CEL-SCI Corporation (CVM), where reflects the most recent value of the metric. This trend captures the shortage of effective treatment methods for head and neck tumors. Multikine technology creates an advantage by activating immunity prior to surgery to increase survival rates. The innovative platform trains the body to fight the disease, improving overall chances of recovery.
Analytical breakdowns for CEL-SCI Corporation
- market price and analyst price targets:
- market capitalization statistics:
- business book valuation details:
- debt and liquidity details:
Total Debt to Capital CEL-SCI Corporation|CVM - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio CEL-SCI|CVM - Aggregate Debt Obligations|Debts to Book Capitalization CEL-SCI Corporation|CVM - Company Long-Term Liabilities|Company Short-Term Debt CEL-SCI|Quick Liquidity cel-sci.com
- business earnings and investment ratios data:
CVM - Final Profit|Expected Profit CEL-SCI Corporation|CVM - Market Cap to Net Income|Future Price to Earnings CEL-SCI|CVM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CEL-SCI Corporation|CVM - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) CEL-SCI|CVM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months cel-sci.com|CVM - Net earnings per one share growth for the current year|Earnings growth forecast for next year CEL-SCI Corporation
- sales volume and revenue indicators:
Summary company analysis:CEL-SCI Corp CVM
The implementation of robotic bioreactors into CEL-SCI Corporation (CVM) immunotherapy production directly impacts future revenue streams, as reflected in the forward P/S ratio dynamics. This indicator compares the company's current market value with expected sales volume, allowing investors to determine the premium paid for future growth and assess the fundamental value of assets relative to their projected returns.
Competitors of CEL-SCI Corporation (CVM)
Price-to-Projected Revenue Ratio BeiGene ONC|Halozyme Therapeutics, Inc. - Price-to-Projected Revenue Ratio|RVMD: Forward Price-to-Revenue Multiple|Projected Price to Revenue Ascentage Pharma Corp (AAPG)|CG Oncology, Inc. (CGON) - Price-to-Projected Revenue Ratio|URGN - Market Cap to Expected Sales Ratio|BCAX (Bicara Therapeutics) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Personalis Inc (PSNL)|Forward P/S Multiple ERAS|Market Cap to Expected Sales Ratio Delcath Corp|Y-mAbs Therapeutics - Forward Price-to-Revenue Multiple|Forward Price to Sales AURA|Candel - Forward P/S Multiple|Accuray Inc (ARAY) - Forward Price-to-Revenue Multiple|sellaslifesciences.com (SLS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Actuate Therapeutics Inc (ACTU)|Price-to-Projected Revenue Ratio Citius Oncology, Inc.|HURA: Forward Price to Sales|Price-to-Projected Revenue Ratio Protara Therapeutics, Inc. (TARA)|FATE: Future Price to Revenue|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|TScan Therapeutics Inc (TCRX) - Market Cap to Future Revenue Ratio|CSBR - Price-to-Projected Revenue Ratio|Forward Price to Sales XBIT (XBiotech Inc.)|OSTX: Forward P/S Multiple|radiopharmtheranostics.com (RADX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ARTV|ANL (Adlai Nortye Limited) - Price to Expected Revenue Ratio|Forward P/S Multiple VERU|Market Cap to Expected Sales Ratio tempesttx.com|Price-to-Projected Revenue Ratio Xilio Therapeutics XLO|Renovaro Biosciences (RENB) - Market Cap to Future Revenue Ratio|MURA - Price-to-Projected Revenue Ratio|KAPA (Kairos Pharma Ltd) - Market Cap to Projected Revenue|OKUR: Forward P/S Multiple|Forward Price-to-Revenue Multiple CytoMed Therapeutics Limited|Forward Price-to-Revenue Multiple CRIS|Price-to-Projected Revenue Ratio APLM|Price-to-Projected Revenue Ratio Tharimmune Corp (THAR)|Forward Price-to-Revenue Multiple advanbiomed.com ADVB|Forward P/S Multiple GNPX (Genprex, Inc.)|CLDI - Forward Price-to-Revenue Multiple|Sunshine Biopharma, Inc. - Forward P/S Multiple|XBIO - Forward P/S Multiple|Salarius (SLRX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue PPBT|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple beigene.com (BGNE)|Forward P/S Multiple CKPT|ELEV - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio iCAD ICAD|Forward Price to Sales IKNA|NTBL: Forward Price-to-Revenue Multiple|Forward Price to Sales VIRX (Viracta Therapeutics)|MOR: Forward P/S Multiple|Forward Price-to-Revenue Multiple NAYA Biosciences Inc|Forward Price-to-Revenue Multiple AAPGV
